Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
; Coria, Mirta Lorena
; Ceballos, Ana
; Mazzitelli, Bianca ; Rodriguez, Juan Manuel ; Demaría, María Agostina
; Pueblas Castro, Celeste Victoria
; Bruno, Laura ; Saposnik, Lucas Martín
; Salvatori, Melina
; Varese, Augusto
; González, Soledad ; González Martínez, Verónica V.
; Geffner, Jorge Raúl
; Álvarez, Diego ; del Priore, Sabrina Alejandra ; Hernando Insua, Andrés C. ; Kaufmann, Ingrid G. ; Di María, Adrián ; Góngora, Adrián ; Sasso, Guillermina ; Stamer, Sebastián ; Cardoso, Regina ; Chajet, Alejandro ; de Oca, Federico Montes ; Vega, Julio ; Lombardo, Daniela Mónica ; Yerino, Gustavo A. ; Fló, Juan ; Cassataro, Juliana 
Otros responsables
Fecha
12/2023
Editorial
Nature Research
Revista
Nature Communications
Título del libro
Nombre del evento
Fecha del evento
Institución organizadora
ISSN
2041-1723
eISSN
ISBN
Idioma
Inglés
Tipo del evento
Clasificación temática
Palabras clave
Resumen
A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called ARVAC CG was selected for a first in human clinical trial. Healthy male and female participants (18-55 years old) with a complete COVID-19-primary vaccine scheme were assigned to receive two intramuscular doses of either a low-dose or a high-dose of ARVAC CG. The primary endpoint was safety. The secondary objective was humoral immunogenicity. Cellular immune responses were studied as an exploratory objective. The trial was prospectively registered in PRIISA.BA (Registration Code 6564) and ANMAT and retrospectively registered in ClinicalTrials.gov (NCT05656508). Samples from participants of a surveillance strategy implemented by the Ministry of Health of the Province of Buenos Aires that were boosted with BNT162b2 were also analyzed to compare with the booster effect of ARVAC CG. ARVAC CG exhibits a satisfactory safety profile, a robust and broad booster response of neutralizing antibodies against the Ancestral strain of SARS-CoV-2 and the Gamma, Delta, Omicron BA.1 and Omicron BA.5 variants of concern and a booster effect on T cell immunity in individuals previously immunized with different COVID-19 vaccine platforms.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa
